The IPO removes near-term financing risk and funds pipeline through 2029, but the stock will trade on clinical catalysts, watch for Phase 3 GT trial initiation in H2 2026 and data readouts for sutacimig (FVII deficiency) and HMB-002 (VWD) in late 2026/early 2027. No revenue or guidance to anchor valuation.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 21 $26.30entry
- T+1 · 6mo ago −1.56%α −2.00% · $25.89
- T+5 · 6mo ago +8.37%α +6.52% · $28.50
- T+20 · 5mo ago +21.03%α +20.69% · $31.83
- T+60 · 3mo ago +103.76%α +99.46% · $53.59
Price Chart
How similar events traded
Executive Summary
Hemab Therapeutics reported a Q1 2026 net loss of $22.7M ($23.98/share), widening from a $15.3M loss ($16.18/share) in Q1 2025, driven by higher R&D and G&A expenses. The company completed a $346.7M IPO in May 2026, extending its cash runway into 2029, and received FDA Breakthrough Therapy Designation for sutacimig in Glanzmann thrombasthenia. As a pre-revenue clinical-stage biotech, the earnings report itself is routine, but the IPO proceeds and regulatory milestone are the key value drivers.
Key Financial Metrics
Key Facts
- Net loss of $22.7M in Q1 2026 vs $15.3M in Q1 2025, driven by R&D expenses of $19.5M (up from $14.1M) and G&A of $4.2M (up from $2.5M).
- Cash, cash equivalents, and marketable securities totaled $163.5M as of March 31, 2026; combined with $317.2M net IPO proceeds in May 2026, cash runway extends into 2029.
- Completed upsized IPO of 19.26M shares at $18.00/share, raising $346.7M in gross proceeds.
- FDA granted Breakthrough Therapy Designation for sutacimig in Glanzmann thrombasthenia in March 2026.
- Phase 3 pivotal trial for sutacimig in GT expected to initiate in H2 2026; Phase 2 data for Factor VII deficiency and Phase 1/2 data for HMB-002 expected in late 2026 or early 2027.
Financial Impact
Net loss widened by $7.4M YoY; IPO added $346.7M gross proceeds; cash runway extended into 2029.
Risk Factors
- Pre-revenue clinical-stage company with no approved products; valuation depends entirely on pipeline success.
- Phase 3 GT trial may fail to meet endpoints; regulatory path for Breakthrough Therapy designation is not guaranteed.
- Cash burn rate is increasing as programs advance; additional financing may be needed beyond 2029.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3299177 |
Track record
19 reports on COAG
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 10, 20266d ago Press Release Neutral 4/10 Entry $38.77 Now $39.06 +0.75% settles Nov 17
- Nov 9, 20267d ago Press Release Bullish 6/10 Entry $42.81 to $39.06 Now $39.06 −8.76% ▼ −8.77% −7.08% vs SPY
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $49.02 to $40.86 Now $39.06 −20.32% ▼ −16.65% −19.24% vs SPY
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $45.09 to $39.33 Now $39.06 −13.37% ▼ −12.77% −11.86% vs SPY
- Sep 25, 20267w ago 3 Neutral 2/10 Entry $33.12 to $30.59 Now $39.06 +17.93% ▼ −7.64% −8.84% vs SPY
- Sep 17, 20268w ago Press Release Neutral 4/10 Entry $41.22 to $35.72 Now $39.06 −5.24% ▼ −13.34% −14.19% vs SPY
- Aug 11, 202613w ago 8-K Bullish 7/10 Entry $49.87 to $52.44 Now $39.06 −21.68% ▲ +5.15% +5.56% vs SPY
- Jun 17, 202621w ago Insider Buy Neutral 2/10 Entry $29.24 to $27.72 Now $39.06 +33.58% ▼ −5.20% −3.53% vs SPY
- May 21, 202625w ago Press Release Neutral 5/10 Viewing Entry $26.30 to $28.50 Now $39.06 +48.52% ▲ +8.37% +6.52% vs SPY
- May 4, 202628w ago 8-K Neutral 4/10 Entry $25.00 to $25.90 Now $39.06 +56.24% ▲ +3.60% +1.62% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers